ArticleJournal of cancer research and clinical oncology2023

Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance.

Lucien Torlot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.